1. Home
  2. BENF vs SCLX Comparison

BENF vs SCLX Comparison

Compare BENF & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beneficient

BENF

Beneficient

HOLD

Current Price

$1.05

Market Cap

34.2M

Sector

Finance

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$2.83

Market Cap

27.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BENF
SCLX
Founded
2003
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.2M
27.9M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
BENF
SCLX
Price
$1.05
$2.83
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 9.4M
38.9K
Earning Date
11-13-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $30,253,000.00
Revenue This Year
N/A
$118.16
Revenue Next Year
N/A
$186.31
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.50
$2.77
52 Week High
$60.00
$27.00

Technical Indicators

Market Signals
Indicator
BENF
SCLX
Relative Strength Index (RSI) 45.39 20.68
Support Level $0.50 N/A
Resistance Level $3.81 $7.77
Average True Range (ATR) 0.15 0.34
MACD 0.01 -0.07
Stochastic Oscillator 31.00 3.78

Price Performance

Historical Comparison
BENF
SCLX

About BENF Beneficient

Beneficient is a technology-enabled financial services holding company providing liquidity solutions and trust products and services to participants in the alternative assets industry through an online platform, AltAccess. Its services are focused on alternative asset investors, institutional investors, family offices, and fund managers. The company provides liquidity solutions for alternative asset investments through financing and trust structures. The company has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts. The majority of revenue is derived from the Ben Liquidity segment in the form of interest income.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: